Transenterix (NYSE: TRXC) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.
Insider & Institutional Ownership
53.3% of Ocular Therapeutix shares are held by institutional investors. 26.1% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Transenterix and Ocular Therapeutix’s gross revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Transenterix has higher revenue and earnings than Ocular Therapeutix.
This is a breakdown of recent ratings for Transenterix and Ocular Therapeutix, as provided by MarketBeat.
||Strong Buy Ratings
Transenterix presently has a consensus price target of $2.75, suggesting a potential upside of 16.03%. Ocular Therapeutix has a consensus price target of $22.29, suggesting a potential upside of 286.23%. Given Ocular Therapeutix’s higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Transenterix.
This table compares Transenterix and Ocular Therapeutix’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Transenterix beats Ocular Therapeutix on 6 of the 11 factors compared between the two stocks.
Transenterix Company Profile
TransEnterix, Inc. is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement. The system replicates laparoscopic motion and integrates three-dimensional high definition (3DHD) vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments. The SurgiBot System is designed as a single-incision, patient-side robotic-assisted surgery system. The Company also develops and manufactures laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.